Skip to content
value.today

GenVec: peers

Change the peers

GenVec beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

GenVec, Mereo BioPharma Group plc, Lipella Pharmaceuticals Inc., Vaccinex, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

GenVec, Mereo BioPharma Group plc, Lipella Pharmaceuticals Inc., Yarrow Bioscience, Inc., Cardiff Oncology, Inc., PMGC Holdings Inc., Vaccinex, Inc., MediciNova, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureGenVecbase
GNVC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Mereo BioPharma Group plc
MREO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Lipella Pharmaceuticals Inc.
LIPO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Yarrow Bioscience, Inc.
YARW · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cardiff Oncology, Inc.
CRDF · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
PMGC Holdings Inc.
ELAB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Vaccinex, Inc.
VCNX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
MediciNova, Inc.
MNOV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)————$6 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 6$307 MOct 28, 2026 · Market data1st of 6$71 MOct 30, 2026 · Market data3rd of 6$24 MOct 14, 2026 · Market data4th of 6$9 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 6$74 MOct 16, 2026 · Market data2nd of 6$47 M6 ranked
Revenue (Better neither way: ranked highest first)$1 MFY2016 · SEC6th of 8$1 MFY2025 · SEC7th of 8$1 MFY2024 · SEC5th of 8$1 MFY2025 · SEC4th of 8$1 MFY2025 · SEC2nd of 8$1 MFY2025 · SEC2nd of 8$1 MFY2024 · SEC1st of 8$0 MFY2025 · SEC8th of 8$1 M8 ranked
Net income (Higher is better)$-6 MFY2016 · SEC2nd of 8$-42 MFY2025 · SEC7th of 8$-5 MFY2024 · SEC1st of 8$-26 MFY2025 · SEC6th of 8$-46 MFY2025 · SEC8th of 8$-8 MFY2025 · SEC3rd of 8$-19 MFY2024 · SEC5th of 8$-12 MFY2025 · SEC4th of 8$-15 M8 ranked
Employees (Better neither way: ranked highest first)15February 28, 2017 · Profile3rd of 4————10December 31, 2025 · Profile4th of 4——32December 31, 2025 · Profile1st of 423December 31, 2024 · Profile2nd of 4——194 ranked
Margins and returns
Return on equity (Higher is better)————-82.2%FY2025 · SEC4th of 630th12th-198.4%FY2024 · SEC6th of 610th4th-66.3%FY2025 · SEC2nd of 635th15th-71.5%FY2025 · SEC3rd of 633rd14th-106.9%FY2025 · SEC5th of 623rd10th————-25.5%FY2025 · SEC1st of 657th25th-76.8%6 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————————625.6×price Oct 28, 2026 · Market data1st of 499th100th128.7×price Oct 30, 2026 · Market data3rd of 495th98th40.9×price Oct 14, 2026 · Market data4th of 490th97th————181.2×price Oct 16, 2026 · Market data2nd of 496th99th155.0×4 ranked
Price to book (Better neither way: ranked highest first)————————————11.0×price Oct 28, 2026 · Market data1st of 486th90th1.6×price Oct 30, 2026 · Market data4th of 432nd38th3.1×price Oct 14, 2026 · Market data2nd of 450th63rd————1.8×price Oct 16, 2026 · Market data3rd of 436th43rd2.4×4 ranked
Free cash flow yield (Higher is better)————————————-10.8%price Oct 28, 2026 · Market data1st of 441st20th-53.6%price Oct 30, 2026 · Market data4th of 417th7th-26.4%price Oct 14, 2026 · Market data3rd of 428th12th————-13.2%price Oct 16, 2026 · Market data2nd of 439th18th-19.8%4 ranked
Financial strength
Debt to equity (Lower is better)————————————0.0×FY2025 · SEConly one with it5th3rd————————————————0.0×—
Interest cover (Higher is better)————-154.3×FY2025 · SEConly one with it10th4th————————————————————————-154.3×—
Scorecard
Scorecard (Higher is better)——2 of 8FY2025 · Scorecard4th of 71 of 6FY2024 · Scorecard5th of 76 of 17FY2025 · Scorecard1st of 72 of 15FY2025 · Scorecard6th of 71 of 9FY2025 · Scorecard7th of 73 of 9FY2024 · Scorecard2nd of 74 of 14FY2025 · Scorecard3rd of 725% passed7 ranked
Valuation checks (Higher is better)——————0 of 5FY2025 · Scorecard3rd of 41 of 5FY2025 · Scorecard1st of 40 of 5FY2025 · Scorecard3rd of 4——1 of 5FY2025 · Scorecard1st of 410% passed4 ranked
Growth checks (Higher is better)——1 of 2FY2025 · Scorecard2nd of 60 of 1FY2024 · Scorecard5th of 61 of 3FY2025 · Scorecard4th of 60 of 3FY2025 · Scorecard5th of 6——2 of 3FY2024 · Scorecard1st of 61 of 2FY2025 · Scorecard2nd of 642% passed6 ranked
Profitability checks (Higher is better)——0 of 2FY2025 · Scorecard1st of 70 of 2FY2024 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70 of 2FY2025 · Scorecard1st of 70 of 2FY2024 · Scorecard1st of 70 of 3FY2025 · Scorecard1st of 70% passed7 ranked
Financial health checks (Higher is better)——1 of 3FY2025 · Scorecard4th of 71 of 2FY2024 · Scorecard2nd of 74 of 5FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 71 of 2FY2025 · Scorecard2nd of 71 of 3FY2024 · Scorecard4th of 71 of 3FY2025 · Scorecard4th of 733% passed7 ranked
Shareholder returns checks (Higher is better)——0 of 1FY2025 · Scorecard3rd of 60 of 1FY2024 · Scorecard3rd of 61 of 1FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard3rd of 6——0 of 1FY2024 · Scorecard3rd of 61 of 1FY2025 · Scorecard1st of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——————61.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 423.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 40.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——16.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 419.9%4 ranked
Institutions holding (Better neither way: ranked highest first)——————492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4752026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 462026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4444 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————-11.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 2————-0.5 pp2026-Q2 against 2026-Q1 · 13F1st of 2-6.1 pp2 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = GenVec: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Mereo BioPharma Group plc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Lipella Pharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Yarrow Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cardiff Oncology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; PMGC Holdings Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vaccinex, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; MediciNova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Return on equity#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Return on equity: each company's figure and its percentile in its sector and its country
CompanyReturn on equityIn its sectorIn its country
GenVec———
Mereo BioPharma Group plc-82.2%FY2025
30th percentile in Healthcaremedian -36.9%, 977 companies
12th percentile in USAmedian 4.8%, 3,580 companies
Lipella Pharmaceuticals Inc.-198.4%FY2024
10th percentile in Healthcaremedian -36.9%, 977 companies
4th percentile in USAmedian 4.8%, 3,580 companies
Yarrow Bioscience, Inc.-66.3%FY2025
35th percentile in Healthcaremedian -36.9%, 977 companies
15th percentile in USAmedian 4.8%, 3,580 companies
Cardiff Oncology, Inc.-71.5%FY2025
33rd percentile in Healthcaremedian -36.9%, 977 companies
14th percentile in USAmedian 4.8%, 3,580 companies
PMGC Holdings Inc.-106.9%FY2025
23rd percentile in Healthcaremedian -36.9%, 977 companies
10th percentile in USAmedian 4.8%, 3,580 companies
Vaccinex, Inc.———
MediciNova, Inc.-25.5%FY2025
57th percentile in Healthcaremedian -36.9%, 977 companies
25th percentile in USAmedian 4.8%, 3,580 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$5 M$10 M$16 M$21 M20102012201420162018202020222024GenVec $1 MMereo BioPharma Group plc $1 MLipella Pharmaceuticals Inc. $1 MYarrow Bioscience, Inc. $1 MCardiff Oncology, Inc. $1 MPMGC Holdings Inc. $1 MVaccinex, Inc. $1 MMediciNova, Inc. $0 M

Rank in the group

1st2nd3rd4th5th6th7th201120122013201420152016201720182019202020212022202320242025GenVec: 1st of 2 in 2011GenVec: 1st of 3 in 2012GenVec: 1st of 2 in 2013GenVec: 1st of 2 in 2014GenVec: 1st of 2 in 2015GenVec: 2nd of 3 in 2016GenVecMereo BioPharma Group plc: 1st of 7 in 2023Mereo BioPharma Group plc: 4th of 5 in 2025Mereo BioPharma Group plcLipella Pharmaceuticals Inc.: 5th of 5 in 2021Lipella Pharmaceuticals Inc.: 5th of 5 in 2022Lipella Pharmaceuticals Inc.: 6th of 7 in 2023Lipella Pharmaceuticals Inc.: 3rd of 4 in 2024Lipella Pharmaceuticals InYarrow Bioscience, Inc.: 1st of 3 in 2016Yarrow Bioscience, Inc.: 1st of 2 in 2017Yarrow Bioscience, Inc.: 1st of 3 in 2018Yarrow Bioscience, Inc.: 2nd of 3 in 2019Yarrow Bioscience, Inc.: 1st of 3 in 2020Yarrow Bioscience, Inc.: 2nd of 5 in 2021Yarrow Bioscience, Inc.: 2nd of 5 in 2022Yarrow Bioscience, Inc.: 7th of 7 in 2023Yarrow Bioscience, Inc.: 4th of 4 in 2024Yarrow Bioscience, Inc.: 3rd of 5 in 2025Yarrow Bioscience, Inc.Cardiff Oncology, Inc.: 2nd of 2 in 2011Cardiff Oncology, Inc.: 3rd of 3 in 2012Cardiff Oncology, Inc.: 2nd of 2 in 2013Cardiff Oncology, Inc.: 2nd of 2 in 2014Cardiff Oncology, Inc.: 2nd of 2 in 2015Cardiff Oncology, Inc.: 3rd of 3 in 2016Cardiff Oncology, Inc.: 2nd of 2 in 2017Cardiff Oncology, Inc.: 3rd of 3 in 2018Cardiff Oncology, Inc.: 3rd of 3 in 2019Cardiff Oncology, Inc.: 3rd of 3 in 2020Cardiff Oncology, Inc.: 4th of 5 in 2021Cardiff Oncology, Inc.: 3rd of 5 in 2022Cardiff Oncology, Inc.: 5th of 7 in 2023Cardiff Oncology, Inc.: 1st of 4 in 2024Cardiff Oncology, Inc.: 1st of 5 in 2025Cardiff Oncology, Inc.PMGC Holdings Inc.: 1st of 5 in 2022PMGC Holdings Inc.: 2nd of 7 in 2023PMGC Holdings Inc.: 1st of 5 in 2025PMGC Holdings Inc.Vaccinex, Inc.: 2nd of 3 in 2018Vaccinex, Inc.: 1st of 3 in 2019Vaccinex, Inc.: 2nd of 3 in 2020Vaccinex, Inc.: 3rd of 5 in 2021Vaccinex, Inc.: 4th of 5 in 2022Vaccinex, Inc.: 4th of 7 in 2023Vaccinex, Inc.: 2nd of 4 in 2024Vaccinex, Inc.MediciNova, Inc.: 2nd of 3 in 2012MediciNova, Inc.: 1st of 5 in 2021MediciNova, Inc.: 3rd of 7 in 2023MediciNova, Inc.: 5th of 5 in 2025MediciNova, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearGenVecMereo BioPharma Group plcLipella Pharmaceuticals Inc.Yarrow Bioscience, Inc.Cardiff Oncology, Inc.PMGC Holdings Inc.Vaccinex, Inc.MediciNova, Inc.
2025—$1 MSEC4th—$1 MSEC3rd$1 MSEC1st$1 MSEC1st—$0 MSEC5th
2024——$1 MSEC3rd$1 MSEC4th$1 MSEC1st—$1 MSEC2nd—
2023—$10 MSEC1st$0 MSEC6th$0 MSEC7th$0 MSEC5th$2 MSEC2nd$1 MSEC4th$1 MSEC3rd
2022——$0 MSEC5th$0 MSEC2nd$0 MSEC3rd$1 MSEC1st$0 MSEC4th—
2021——$0 MSEC5th$1 MSEC2nd$0 MSEC4th—$1 MSEC3rd$4 MSEC1st
2020———$21 MSEC1st$0 MSEC3rd—$1 MSEC2nd—
2019———$0 MSEC2nd$0 MSEC3rd—$1 MSEC1st—
2018———$11 MSEC1st$0 MSEC3rd—$1 MSEC2nd—
2017———$5 MSEC1st$1 MSEC2nd———
2016$1 MSEC2nd——$1 MSEC1st$0 MSEC3rd———
2015$1 MSEC1st———$0 MSEC2nd———
2014$6 MSEC1st———$0 MSEC2nd———

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of GenVec#

Companies of the same industry, within a hundred times its size (latest annual revenue), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Mereo BioPharma Group plcMREO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Lipella Pharmaceuticals Inc.LIPO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Yarrow Bioscience, Inc.YARW · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $307 M (Oct 28, 2026) · revenue $1 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Cardiff Oncology, Inc.CRDF · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $71 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • PMGC Holdings Inc.ELAB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $24 M (Oct 14, 2026) · revenue $1 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Vaccinex, Inc.VCNX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $9 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • MediciNova, Inc.MNOV · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $74 M (Oct 16, 2026) · revenue $0 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Bio Green Med Solution, Inc.BGMS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6 M (Oct 26, 2026) · revenue $1 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    + Add
  • Provectus Biopharmaceuticals Inc.PVCT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $46 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • ImageneBio, Inc.IMA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $50 M (Oct 27, 2026) · revenue $1 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Seres Therapeutics, Inc.MCRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Allarity Therapeutics, Inc.ALLR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14 M (Oct 15, 2026) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.